As at September 2024, Passage Bio had cash of US$85m and no debt. Importantly, its cash burn was US$59m over the trailing twelve months. Therefore, from September 2024 it had roughly 17 months of ...

Passage Bio, Inc., a biotechnology firm specializing in biological products, has transferred its stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transition ...

A high-level overview of Passage Bio, Inc. (PASG) stock. View ... IPO Update: Passage Bio Finalizes $126 Million IPO Plan ... Is Passage Bio, Inc. listed on the NASDAQ or NYSE?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring ...

On September 19, 2024, Orbimed Advisors LLC, a prominent investment firm, executed a significant transaction involving the shares of Passage Bio Inc (NASDAQ:PASG). Despite this reduction, Orbimed ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Wedbush assumed coverage of Passage Bio (PASG) with an Outperform rating and price target of $4, up from $3. Market sentiment may be different from the days when an extensive gene therapy pipeline ...

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative ...

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced encouraging updates from the ongoing Phase 1/2 upliFT-D ...

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew ...

In March 2024, Passage Bio had US$105m in cash, and was debt-free. Looking at the last year, the company burnt through US$75m. That means it had a cash runway of around 17 months as of March 2024.